Reata manages a portfolio of innovative drug development projects addressing major unmet medical needs

Overview

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting innovative technologies and translating them into marketed drugs that address major unmet needs in intractable diseases such as cancer, inflammation and neurodegenerative disease.

The company’s two lead programs have produced impressive results in early human trials and are in Phase 2 trials for deadly, late stage cancers as well as renal/cardiovascular and autoimmune diseases.

Behind these lead programs, the Reata portfolio includes two technology platforms in important emerging areas of biology. Reata is the leader in developing Antioxidant Inflammation Modulating (AIM) drugs. This class of drugs promotes the resolution of innate and adaptive immune-mediated inflammation by restoring redox homeostasis in inflamed tissues and has applications in a broad range of indications. Additionally, Reata is a leader in discovering drugs that correct protein misfolding and has a proprietary screening technology to enable high throughput drug discovery of small molecules that modulate the protein folding process.

Strategy
Reata approaches each product opportunity with a combination of superior technology assessment, an unparalleled ability to collaborate, highly efficient development processes and tight integration of scientific and business insights. Reata manages its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Company operations, partnering relationships and development decisions are structured to maximize the number of opportunities for success in the clinic in the shortest possible time and at the lowest possible cost.